Interim Management Statement Q1 2024 of Molecular Partners: Pipeline Progressing with Two Additional Programs to Enter the Clinic in 2025, Update to MP0533 Program

May 16, 2024

https://www.globenewswire.com/news-release/2024/05/16/2883849/0/en/Interim-Management-Statement-Q1-2024-of-Molecular-Partners-Pipeline-Progressing-with-Two-Additional-Programs-to-Enter-the-Clinic-in-2025-Update-to-MP0533-Program.html

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., May 16, 2024 (GLOBE NEWSWIRE) —  Ad hoc announcement pursuant to Art. 53 LR   Molecular Partners AG (SIX: MOLN; NASDAQ:MOLN), a clinical-stage biotech company pioneering the design and development of DARPin therapeutics for medical challenges that other drug modalities cannot readily address (“Molecular Partners” or the “Company”), today announced corporate highlights and unaudited financial results for the first quarter of 2024.

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.